Related Experiment Videos
Imatinib (Gleevec)-induced hepatotoxicity
Walid S Ayoub1, Stephen A Geller, Tram Tran
1Center for Liver and Kidney Diseases and Transplantation, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
Journal of Clinical Gastroenterology
|December 16, 2004
Summary
Imatinib, a cancer drug, can cause liver damage (hepatotoxicity). This report details a new case of Imatinib-induced hepatotoxicity, including its histopathology and clinical outcome after drug withdrawal.
Area of Science:
- Hepatology
- Oncology
- Pharmacology
Background:
- Imatinib (Gleevec) is a crucial targeted therapy for chronic myelogenous leukemia and gastrointestinal stromal tumors.
- Drug-induced liver injury is a significant concern in clinical practice.
- Histologically proven Imatinib-induced hepatotoxicity is rare, with limited published cases.
Observation:
- A 22-year-old female patient developed liver injury during Imatinib treatment.
- The case involved detailed histopathologic examination of liver tissue.
- Clinical data documented the patient's course following Imatinib discontinuation.
Findings:
- This case adds to the scarce literature on Imatinib-induced hepatotoxicity.
- Histopathological findings provide insights into the mechanism of liver injury.
- Discontinuation of Imatinib led to the resolution of liver injury.
Implications:
- Clinicians should be vigilant for potential hepatotoxicity in patients receiving Imatinib.
- Further research may elucidate the mechanisms underlying Imatinib-induced liver injury.
- Early recognition and management are crucial for patient outcomes.